163 related articles for article (PubMed ID: 17322463)
41. Radiologically significant joint improvement in a patient affected by psoriatic arthritis treated with adalimumab.
Chimenti MS; Papoutsaki M; Teoli M; Zangrilli A; Perricone R; Chimenti S
Clin Exp Rheumatol; 2009; 27(6):1056. PubMed ID: 20149332
[No Abstract] [Full Text] [Related]
42. Biologic agents in the management of inflammatory eye diseases.
Michalova K; Lim L
Curr Allergy Asthma Rep; 2008 Jul; 8(4):339-47. PubMed ID: 18606088
[TBL] [Abstract][Full Text] [Related]
43. Pregnancy during adalimumab use for psoriasis.
Dessinioti C; Stefanaki I; Stratigos AJ; Kostaki M; Katsambas A; Antoniou C
J Eur Acad Dermatol Venereol; 2011 Jun; 25(6):738-9. PubMed ID: 20569288
[No Abstract] [Full Text] [Related]
44. Letter: are infliximab and adalimumab similar for Crohn's disease in clinical practice?
Tursi A; Elisei W; Picchio M; Penna A
Aliment Pharmacol Ther; 2013 Apr; 37(7):763-4. PubMed ID: 23458543
[No Abstract] [Full Text] [Related]
45. Adalimumab therapy for refractory uveitis: a pilot study.
Diaz-Llopis M; García-Delpech S; Salom D; Udaondo P; Hernández-Garfella M; Bosch-Morell F; Quijada A; Romero FJ
J Ocul Pharmacol Ther; 2008 Jun; 24(3):351-61. PubMed ID: 18476805
[TBL] [Abstract][Full Text] [Related]
46. Anti-tumor necrosis factor-α therapy in uveitis.
Cordero-Coma M; Sobrin L
Surv Ophthalmol; 2015; 60(6):575-89. PubMed ID: 26164735
[TBL] [Abstract][Full Text] [Related]
47. [Patient information. Biological agents in inflammatory bowel disease].
Van Domselaar M
Rev Esp Enferm Dig; 2008 Dec; 100(12):798. PubMed ID: 19238770
[No Abstract] [Full Text] [Related]
48. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
[TBL] [Abstract][Full Text] [Related]
49. Comparison of the acute effects of anti-TNF-alpha drugs on a uveitis experimental model.
Johnsen-Soriano S; Sancho-Tello M; Arnal E; Díaz-Llopis M; Navea A; Miranda M; Bosch-Morell F; Romero FJ
Ocul Immunol Inflamm; 2010 Jun; 18(3):208-15. PubMed ID: 20482400
[TBL] [Abstract][Full Text] [Related]
50. Serum cytokine profile in adalimumab-treated refractory uveitis patients: decreased IL-22 correlates with clinical responses.
Cordero-Coma M; Calleja S; Llorente M; Rodriguez E; Franco M; Ruiz de Morales JG
Ocul Immunol Inflamm; 2013 Jun; 21(3):212-9. PubMed ID: 23617852
[TBL] [Abstract][Full Text] [Related]
51. Treatment of inflammatory immunologic disease 3. Anti-TNF therapy in rheumatoid arthritis.
Takeuchi T
Intern Med; 2007; 46(16):1311-2. PubMed ID: 17704613
[No Abstract] [Full Text] [Related]
52. Optic neuritis associated with adalimumab in the treatment of uveitis.
Li SY; Birnbaum AD; Goldstein DA
Ocul Immunol Inflamm; 2010 Dec; 18(6):475-81. PubMed ID: 20809867
[TBL] [Abstract][Full Text] [Related]
53. Adalimumab for the treatment of ankylosing spondylitis.
Sieper J; Rudwaleit M; Braun J
Expert Opin Pharmacother; 2007 Apr; 8(6):831-8. PubMed ID: 17425478
[TBL] [Abstract][Full Text] [Related]
54. Adalimumab-induced psoriasis of the scalp with diffuse alopecia: a severe potentially irreversible cutaneous side effect of TNF-alpha blockers.
El Shabrawi-Caelen L; La Placa M; Vincenzi C; Haidn T; Muellegger R; Tosti A
Inflamm Bowel Dis; 2010 Feb; 16(2):182-3. PubMed ID: 19462433
[No Abstract] [Full Text] [Related]
55. Urticaria and angioedema in a patient with Behçet's disease treated with adalimumab.
Sànchez-Cano D; Callejas-Rubio JL; Ortego-Centeno N; Ruiz-Villaverde R
Clin Exp Rheumatol; 2006; 24(5 Suppl 42):S128. PubMed ID: 17067448
[No Abstract] [Full Text] [Related]
56. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
[TBL] [Abstract][Full Text] [Related]
57. Intestinal Behçet's disease: maintenance of remission with adalimumab monotherapy.
Ariyachaipanich A; Berkelhammer C; Nicola H
Inflamm Bowel Dis; 2009 Dec; 15(12):1769-71. PubMed ID: 19177427
[No Abstract] [Full Text] [Related]
58. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.
Zannin ME; Birolo C; Gerloni VM; Miserocchi E; Pontikaki I; Paroli MP; Bracaglia C; Shardlow A; Parentin F; Cimaz R; Simonini G; Falcini F; Corona F; Viola S; De Marco R; Breda L; La Torre F; Vittadello F; Martini G; Zulian F
J Rheumatol; 2013 Jan; 40(1):74-9. PubMed ID: 23118110
[TBL] [Abstract][Full Text] [Related]
59. The influence of uveitis on patients with immune-mediated inflammatory disease.
Rosenbaum JT; Russell AS; Guenther LC; El-Gabalawy H
J Rheumatol Suppl; 2011 Nov; 88():26-30. PubMed ID: 22045975
[TBL] [Abstract][Full Text] [Related]
60. Tumor Necrosis Factor Inhibitors Provide Longterm Clinical Benefits in Pediatric and Young Adult Patients with Blau Syndrome.
Nagakura T; Wakiguchi H; Kubota T; Yamatou T; Yamasaki Y; Nonaka Y; Nerome Y; Akaike H; Takezaki T; Imanaka H; Kawano Y; Takei S
J Rheumatol; 2017 Apr; 44(4):536-538. PubMed ID: 28604349
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
